Lidbree (Lidocaine)

• Lidocaine in Lidbree provides local anesthesia for procedures involving the cervix and uterus.
• Cervical dilation: reduces pain and discomfort during mechanical dilation of the cervix.
• Intrauterine device insertion: numbs the uterine lining to facilitate painless IUD placement.
• Minor gynecologic surgeries: offers targeted anesthesia for small operative interventions within the female reproductive tract.

• Lidocaine acts by reversibly binding to voltage‑gated sodium channels on neuronal membranes, stabilizing the inactive state of the channel and preventing the rapid influx of sodium ions required for depolarization. This blockade halts the propagation of nerve impulses along sensory fibers, resulting in a localized loss of sensation without affecting surrounding tissues.

Lidbree may cause a range of adverse reactions, most of which are related to the local anesthetic properties of lidocaine.

Common Side Effects

• Burning or stinging at the application site
• Transient dizziness or light‑headedness
• Nausea or mild vomiting
• Mild headache

Serious or Rare Side Effects

• Systemic toxicity leading to seizures or cardiac arrhythmia
• Severe allergic reaction such as anaphylaxis
• Methemoglobinemia
• Persistent numbness beyond the intended area

• When using Lidbree, several safety considerations should be observed to minimize risk.
• Allergy assessment: verify no known hypersensitivity to lidocaine or other amide‑type anesthetics.
• Cardiovascular monitoring: observe heart rate and rhythm during and after administration.
• Dose limitation: use the lowest effective volume for the specific procedure.
• Hepatic function: exercise caution in patients with severe liver disease.
• Drug interactions: review concomitant medications that may affect lidocaine metabolism.
• Store at room temperature: keep in original container, protect from moisture and light.

Lidbree can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Class I antiarrhythmic agents (e.g., quinidine, procainamide): may increase plasma lidocaine levels and toxicity.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise lidocaine concentrations.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may enhance lidocaine’s cardiac depressant effects.
• Diuretics (e.g., furosemide): may reduce plasma protein binding, increasing free lidocaine.
• General anesthetics (e.g., propofol, inhalational agents): additive central nervous system depression.
• CYP1A2 inducers (e.g., carbamazepine): may lower lidocaine levels.